Comparison of pyrroloquinoline quinone and/or metoprolol on myocardial infarct size and mitochondrial damage in a rat model of ischemia/reperfusion injury

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 11, Issue 2, 2006, Pages 119-128

  Zhu, Bo Qing ^a,b   Simonis, Ursula ^c   Cecchini, Gary ^a,b   Zhou, Hui Zhong ^a,b   Li, Luyi ^a   Teerlink, John R ^a,b   Karliner, Joel S ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO STATE UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Ischemia reperfusion; Metoprolol; Pyrroloquinoline quinone

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; MALONALDEHYDE; METOPROLOL; PYRROLOQUINOLINEQUINONE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE ISCHEMIA; HEART PROTECTION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LIPID PEROXIDATION; LOW DRUG DOSE; MALE; MITOCHONDRIAL MYOPATHY; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIOXIDANTS; BODY WEIGHT; CARDIOTONIC AGENTS; CREATINE KINASE; DRUG INTERACTIONS; HEMODYNAMIC PROCESSES; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; METOPROLOL; MITOCHONDRIA, HEART; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PQQ COFACTOR; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR FIBRILLATION;

EID: 33749016048     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248406288757     Document Type: Article

References (51)

1. McIntire WS. Newly discovered redox cofactors: possible nutritional, medical, and pharmacological relevance to higher animals. Annu Rev Nutr. 1998;18:145-177.
2. Magnusson OT, Toyama H, Saeki M, et al. Quinone biogenesis: structure and mechanism of PqqC, the final catalyst in the production of pyrroloquinoline quinone. Proc Natl Acad Sci U S A. 2004;101:7913-7918.
3. Liu S, Li H, Yang JO, et al. Enhanced rat sciatic nerve regeneration through silicon tubes filled with pyrroloqunioline quinone. Microsurgery. 2005;25:329-337.
4. He K, Nukada H, Urakami T, Murphy MP. Antioxidant and pro-oxidant properties of pyrroloquinoline quinone (PQQ): implications for its function in biological systems. Biochem Pharmacol. 2003;65:67-74.
5. Zhang Y, Rosenberg PA. The essential nutrient pyrroloquinoline quinone may act as a neuroprotectant by suppressing peroxynitrite formation. Eur J Neurosci. 2002;16:1015-1024.
6. Misra HS, Khairnar NP, Barik A, Priyadarsini I, Mohan H, Apte SK. Pyrroloquinoline quinone: a reactive oxygen species scavenger in bacteria. FEBS Lett. 2004;578:26-30.
7. Zhu B-Q, Zhou H-Z, Teerlink JR, Karliner JS. Pyrroloquinoline quinone (PQQ) decreases myocardial infarct size and improves cardiac function in rat models of ischemia and ischemia/reperfusion. Cardiovasc Drugs Therap. 2004;18:421-431.
8. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med. 1990;9:515-540.
9. Rosenson RS, Reeder Guy S, Kennedy HL. Beta blockers in acute myocardial infarction. UpToDate Online 13.2, 2005. Available at: www.uptodate.com.
10. Lysko PG, Webb CL, Gu JL, Ohlstein EH, Ruffolo RR, Yue TL. A comparison of carvedilol and metoprolol antioxidant activities in vitro. Cardiovasc Pharmacol. 2000;36:277-281.
11. Bernauer W. The effect of beta-adrenoceptor blocking agents in evolving myocardial necrosis in coronary ligated rats with and without reperfusion. Naunyn-Schmiedeberg's Arch Pharmacol. 1985;328:288-294.
12. Smith EF III, Griswold DE, Hillegass LM, Slivjak MJ, Davis PA, DiMartino MJ. Cardioprotective effects of vasodilator/ beta-adrenoceptor blocker, carvedilol, in two models of myocardial infarction in the rat. Pharmacology. 1992;44:297-305.
13. Hjalmarson A. Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter? Basic Res Cardiol. 2000;95:I41-I45.
14. Khandoudi N., Percevault-Albadine J, Bril A. Comparative effects of carvedilol and metoprolol on cardiac ischemia-reperfusion injury. J Cardiovasc Pharmacol. 1998;32:443-451.
15. Vik-Mo H, Maroko PR, Ribeiro LG. Comparative effects of propranolol, timolol and metoprolol on myocardial infarct size after experimental coronary artery occlusion. J Am Coll Cardiol. 1984;4:735-741.
16. Rasmussen MM, Reimer KA, Kloner RA, Jennings RB. Infarct size reduction by propranolol before and after coronary ligation in dogs. Circulation. 1977;56:794-798.
17. Hochman JS, Wong S-C. Effect of atenolol on myocardial infarct expansion in a nonreperfused rat model. Am Heart J. 1991;122:689-694.
18. Jain P, Lillis O, Cohn PF. Effects of metoprolol on early infarct expansion after acute myocardial infarction. Am Heart J. 1994; 127:764-773.
19. Kudoh Y, Maxwell MP, Hearse DJ, Downey JM, Yellon DM. Inability of metoprolol to achieve a sustained limitation of infarction 24 h after coronary artery embolization in the closed chest dog. J Cardiovasc Pharmacol. 1984;6:1201-1209.
20. Peter T, Heng MK, Singh BN, et al. Failure of high doses of propranolol to reduce experimental myocardial ischemic damage. Circulation. 1978;57:534-540.
21. Lange R, Nieminen MS, Kloner RA. Failure of pindolol and metoprolol to reduce the size of non-reperfused infarct in dogs using area at risk techniques. Cardiovasc Res. 1984;18:37-43.
22. Bonnemeier H, Ortak J, Tolg R, et al. Carvedilol versus metoprolol in the acute phase of myocardial infarction. Pacing Clin Electrophysiol. 2005;28:S222-S226.
23. Oliveira PJ, Goncalves L, Monteiro P, Providencia LA, Moreno AJ. Are the antioxidant properties of carvedilol important for the protection of cardiac mitochondria? Curr Vasc Pharmacol. 2005;3:147-158.
24. Carreira R, Duarte A, Monteiro P, et al. Carvedilol protects ischemic cardiac mitochondria by preventing oxidative stress. Rev Port Cardiol. 2004;23:1447-1455.
25. Oliveira PJ, Bjork JA, Santos MS, et al. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol. 2004;15;200: 159-168.
26. Oliveira PJ, Esteves T, Rolo AP, Palmeira CM, Moreno AJ. Carvedilol inhibits the mitochondrial permeability transition by an antioxidant mechanism. Cardiovasc Toxicol. 2004;4:11-20.
27. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351-358.
28. Moritz F, Monteil C, Isabelle M, et al. Role of reactive oxygen species in cocaine-induced cardiac dysfunction. Cardiovasc Res. 2003;59:834-843.
29. Watanabe A, Hobara N, Ohsawa T, Higashi T, Tsuji T. Nephrotoxicity of pyrroloquinoline quinone in rats. Hiroshima J Med Sci. 1989;38:49-51.
30. Hocht C, Verniero CD, Opezzo JAW, Taira CA. In vivo and in vitro pharmacodynamic properties of metoprolol in aortic coarcted rats. Pharmacol Res. 2003;47:181-188.
31. Billinger M, Raeber L, Seiler C, Windecker S, Meier B, Hess OM. Coronary collateral perfusion in patients with coronary artery disease: effect of metoprolol. Eur Heart J. 2004;25:565-570.
32. Grimm D, Holmer SR, Riegger GA, Kromer EP. Effects of beta-receptor blockade and angiotensin II type I receptor antagonism in isoproterenol-induced heart failure in the rat. Cardiovasc Pathol. 1999;8:315-323.
33. Kobayashi M, Machida N, Mitsuishi M, Yamane Y. Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure. Am J Hypertens. 2004;17:1112-1119.
34. Min J-Y, Ding B, Wang J-F, Sullivan MF, Morgan JP. Metoprolol attenuates postischemic depressed myocardial function in papillary muscles isolated from normal and postinfarction rat hearts. Eur J Pharmcol. 2001;422:115-125.
35. Omerovic E, Bollano E, Soussi B, Waagstein F. Selective beta-1 blockade attenuates post-infarct remodeling without improvement in myocardial energy metabolism and function in rats with heart failure. Eur J Heart Fail. 2003;5:725-732.
36. Omerovic E, Bollano E, Mobini R, Madhu B, Kujacic V. Selective beta-1 blockade improves cardiac bioenergetics and function and decreases neuroendocrine activation in rats during early postinfarct remodeling. Biochem Biophysic Res Commun. 2001;281:491-498.
37. Theres HP, Wagner KD, Romberg D, et al. Combined treatment with ramipril and metoprolol prevents changes in the creatine kinase isoenzyme system and improves hemodynamic function in rat hearts after myocardial infarction. Cardiovasc Drugs Ther. 2000;14:597-606.
38. Bollano E, Bergh C-H, Kjellstrom C, et al. Growth hormone alone or combined with metoprolol preserves cardiac function after myocardial infarction in rats. Eur J Heart Fail. 2001; 3:651-660.
39. Iwai T, Tanonaka K, Kasahara S, Inoue R, Takeo S. Protective effect of propranolol on mitochondrial function in the ischemic heart. Br J Pharmacol. 2002;136:472-480.
40. Kotsinas A, Gorgoulis V, Zacharatos P, et al. Antioxidant agent nimesulid and beta-blocker metoprolol do not exert protective effects rat mitochondrial DNA alterations in Adriamycin-induced cardiotoxicity. Biochem Biophys Res Commun. 1999; 254:651-656.
41. Roth E, Torok B, Pollak Z, Temes G, Morvay G. Myocardial protection by antioxidant during permanent and temporary coronary occlusion on dogs. Basic Res Cardiol. 1987;82(suppl) 2:335-345.
42. Rousou AJ, Ericsson M, Federman M, Levitsky S, McCully JD. Opening of mitochondrial KATP channels enhances cardioprotection through the modulation of mitochondrial matrix volume, calcium accumulation, and respiration. Am J Physiol Heart Circ Physiol. 2004;287:H1967-H1976.
43. Quinn PJ, Crutcher EC. The action of beta-adrenoceptor antagonist on rat heart mitochondrial function in vitro: a comparison of propranolol, timolol, and atenolol. Cardiovasc Res. 1984;18:212-219.
44. Katyare SS, Rajan RR. Altered energy coupling in rat heart mitochondria following in vivo treatment with propranolol. Biochem Pharmacol. 1991;42:617-623.
45. Dreisbach AW, Greif RL, Lorenzo BJ, Reidenberg MM. Lipophilic beta-blockers inhibit rat skeletal muscle mitochondrial respiration. Pharmacology. 1993;47:295-299.
46. Oliveira PJ, Rolo AP, Sardao VA, et al. Advantages in the use of carvedilol versus propranolol for the protection of cardiac mitochondrial function. Rev Port Cardiol. 2004;23:1291-1298.
47. Yang Z, Berr SS, Gilson WD, Toufektsian M-C, French BA. Simultaneous evaluation of infarct size and cardiac function in intact mice by contrast-enhanced cardiac magnetic resonance imaging reveals contractile dysfunction in noninfarcted regions early after myocardial infarction. Circulation. 2004; 109:1161-1167.
48. Kramer CM, Rogers WJ, Theobald TM, Power TP, Petruolo S, Reichek N. Remote noninfarcted region dysfunction soon after first anterior myocardial infarction: a magnetic resonance tagging study. Circulation. 1996;94:660-666.
49. Jenkins RR, Del Signore CM, Sauer P, Skelly C. The effect of beta blocking drugs on lipid peroxidation in rat heart in vitro. Lipids. 1992;27:539-542.
50. Stanley W, Hoppel CL. Mitochondrial dysfunction in heart failure: potential for therapeutic interventions? Cardiovasc Res. 2000;45:805-806.
51. Lesnefsky EJ, Moghaddas S, Tandler B, Kerner J, Hoppel CL. Mitochondrial dysfunction in cardiac disease: ischemia-reperfusion, aging, and heart failure. J Mol Cell Cardiol. 2001;1065-1089.